SG3 Management’s Inovio Pharmaceuticals INO Stock Holding History

SG3 Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,583	Closed	-$1.06M	–	1107
2020 Q3	$1.06M	Buy	7,583 +5,833	+333%	+$1.22M	0.04%	410
2020 Q2	$566K	Buy	+1,750	New	+$281K	0.04%	372

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG3 Management's INO Position: Q4 2020 in Review

SG3 Management sold out of Inovio Pharmaceuticals (INO) in Q4 2020, closing a stake of 1,667 shares — an estimated $232K sold.

SG3 Management first reported a position in INO in Q2 2018 and held it in 2 quarters. The position peaked at $232K in Q3 2020. 227 funds tracked by Wall St. Rank hold INO as of Q4 2020.

SG3 Management reported no remaining Inovio Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
SG3 Management sold 1,667 Inovio Pharmaceuticals shares in Q4 2020, an estimated $232K.
SG3 Management first reported a position in Inovio Pharmaceuticals in Q2 2018 and held it in 2 quarters.
SG3 Management's Inovio Pharmaceuticals position peaked at $232K in Q3 2020.
227 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.